Proguanil Hydrochloride

This article examines the use of Proguanil Hydrochloride in clinical trials for malaria prevention and treatment. Proguanil is often used in combination with other antimalarial drugs, particularly atovaquone, to create effective treatments against Plasmodium falciparum malaria. The trials explore various aspects including drug efficacy, safety, pharmacokinetics, and potential drug interactions.

Table of Contents

What is Proguanil Hydrochloride?

Proguanil hydrochloride is an antimalarial medication used to prevent and treat malaria, a serious parasitic disease transmitted by mosquitoes[1]. It is often referred to simply as “proguanil” in medical contexts. This drug is frequently used in combination with other antimalarial agents to enhance its effectiveness against the malaria-causing parasite, Plasmodium falciparum.

Uses of Proguanil Hydrochloride

Proguanil hydrochloride is primarily used for:

  • Malaria Prevention (Prophylaxis): It is commonly used by travelers to malaria-endemic areas to prevent infection[2].
  • Treatment of Uncomplicated Malaria: When combined with other drugs, it is used to treat mild to moderate malaria infections[3].

Combination Therapies

Proguanil is often used in combination with other antimalarial drugs to increase effectiveness and reduce the risk of drug resistance. The most common combinations include:

  • Atovaquone-Proguanil: This combination, often sold under the brand name Malarone, is widely used for both prevention and treatment of malaria[1][3].
  • Artesunate-Atovaquone-Proguanil (ASAP): This triple combination is being studied for its potential to combat drug-resistant malaria strains[3].

How Proguanil Works

Proguanil works by interfering with the malaria parasite’s ability to reproduce and survive in the human body. It is converted in the body to an active form called cycloguanil, which blocks an enzyme the parasite needs to make DNA and other important molecules[4]. This action helps to prevent the parasite from multiplying and spreading in the bloodstream.

Dosage and Administration

The dosage of proguanil can vary depending on whether it’s being used for prevention or treatment, and whether it’s being used alone or in combination with other drugs. Some common dosages include:

  • For malaria prevention: A typical adult dose of atovaquone-proguanil (Malarone) is 250mg/100mg taken daily[5].
  • For malaria treatment: Higher doses may be used, such as 1000mg atovaquone/400mg proguanil daily for three days[1].

Always follow your healthcare provider’s instructions regarding dosage and duration of treatment.

Side Effects and Safety

Like all medications, proguanil can cause side effects, although not everyone experiences them. Common side effects may include:

  • Stomach upset or nausea
  • Diarrhea
  • Headache
  • Mouth ulcers

More serious side effects are rare but can occur. Always inform your doctor of any unusual symptoms or side effects[6].

Drug Interactions

Proguanil can interact with other medications, potentially affecting how well they work or increasing the risk of side effects. Some important interactions to be aware of include:

  • HIV Medications: Some antiretroviral drugs used to treat HIV may decrease the effectiveness of proguanil[2].
  • Stomach Acid Reducers: Medications that reduce stomach acid, such as proton pump inhibitors, may affect how proguanil is absorbed by the body[5].

Always inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements.

Ongoing Research

Researchers continue to study proguanil and its combinations to improve malaria treatment and prevention strategies. Some areas of ongoing research include:

  • Evaluating the effectiveness of different dosages and combinations against drug-resistant malaria strains[3].
  • Investigating the impact of genetic variations on how individuals metabolize proguanil[4].
  • Exploring new combination therapies that include proguanil for improved malaria prevention and treatment[7].
Aspect Details
Primary Use Prevention and treatment of malaria
Common Combination Atovaquone-Proguanil (Malarone)
Administration Oral tablets
Key Study Objectives Efficacy, safety, pharmacokinetics, drug interactions
Target Populations Healthy volunteers, malaria patients, individuals with specific genetic variations
Genetic Considerations CYP2C19 enzyme variations may affect drug metabolism
Potential Benefits Effective against drug-resistant strains of malaria
Safety Monitoring Adverse events, vital signs, laboratory tests

Ongoing Clinical Trials on Proguanil Hydrochloride

  • Study on the Effectiveness of Atovaquone and Proguanil for Malaria Prevention in Healthy Volunteers

    Recruiting

    2 1 1
    Germany
  • Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Belgium Bulgaria France Germany Hungary Italy +4

Glossary

  • Proguanil Hydrochloride: An antimalarial drug often used in combination with atovaquone for the prevention and treatment of malaria.
  • Atovaquone: An antiparasitic medication commonly combined with proguanil for malaria prevention and treatment.
  • Plasmodium falciparum: A species of parasite that causes the most severe form of malaria in humans.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • CYP2C19: An enzyme in the liver that plays a role in metabolizing certain drugs, including proguanil.
  • Malaria prophylaxis: The use of medication to prevent malaria infection.
  • Uncomplicated malaria: A form of malaria that has symptoms but no signs of severe disease or organ dysfunction.
  • PCR: Polymerase Chain Reaction, a method used to detect and measure parasites in the blood.
  • Gametocytes: The sexual stage of the malaria parasite that can be transmitted from humans to mosquitoes.
  • Chemoprophylaxis: The use of drugs to prevent disease, in this context, to prevent malaria infection.

References

  1. https://clinicaltrials.gov/study/NCT01858831
  2. https://clinicaltrials.gov/study/NCT00421473
  3. https://clinicaltrials.gov/study/NCT02297477
  4. https://clinicaltrials.gov/study/NCT01456546
  5. https://clinicaltrials.gov/study/NCT04568772
  6. https://clinicaltrials.gov/study/NCT02858817
  7. https://clinicaltrials.gov/study/NCT05974267